Model N, Inc. a leading revenue management solutions provider to the life science and technology industries, and Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) a leading specialty pharmaceutical manufacturer, announced that Salix is live on the latest release of Model N’s Revenue Management suite. With the recent acquisition of Santarus, Inc. (SNTS), Salix continues to expand their product pipeline and diversify revenues. Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) net profit margin is 6.90% and weekly performance is 6.20%. On last trading day company shares ended up $114.18. Analysts mean target price for the company is $124.57. Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) distance from 50-day simple moving average (SMA50) is 6.89%.
Cell Therapeutics Inc (NASDAQ:CTIC)’ stock was initiated with a Buy at Ladenburg on May 22 and price target set at $6. Cell Therapeutics Inc (NASDAQ:CTIC) shares fell -0.35% in last trading session and ended the day on $2.86. Gross Margin is 99.40% and its return on assets is -90.10%. Cell Therapeutics Inc (NASDAQ:CTIC) quarterly performance is -19.66%.
Nektar Therapeutics (NASDAQ:NKTR) a biopharmaceutical company developing novel pain and cancer therapeutics, announced that Ivan Gergel, M.D., will serve as the Company’s new Senior Vice President, Drug Development & Chief Medical Officer effective. Dr. Gergel will have oversight for the company’s clinical strategy and activities, including direct supervision of clinical research, clinical operations, medical affairs, regulatory affairs, and drug safety and surveillance. Nektar Therapeutics (NASDAQ:NKTR) was closed at $11.68, while trading in range of $11.52 – $11.86. Nektar Therapeutics (NASDAQ:NKTR) year to date (YTD) performance is 2.91%.
Amgen Inc. (NASDAQ:AMGN) said Friday its cancer drug Vectibix received expanded approval in the U.S. to treat patients with a genetic variation of advanced colon cancer. The company said the Food and Drug Administration cleared its biotech drug as a first-choice option against colorectal tumors with an abnormal gene known as KRAS, in combination with chemotherapy. Amgen, Inc. (NASDAQ:AMGN) ended the last trading day at $114.33. Company weekly volatility is calculated as 1.52% and price to cash ratio as 4.37. Amgen, Inc. (NASDAQ:AMGN) showed a positive weekly performance of 2.14%.
News of the Chinese authorities visiting Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY)’s operations in China has come a time when officials are looking into the sales practices of many players of the pharmaceutical industry in the country. Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) On last trading day company shares ended up $37.42 .
Leave a Reply